SCHEMBL7182796

SCHEMBL7182796

Cc1cc(C)c(C(=O)[P](=O)c2ccccc2C(=O)c2c(Cl)cc(Cl)cc2Cl)c(C)c1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 1/20 0.36
RORC P51449 4/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
MAPK13 O15264 3/20 0.33
MAPK12 P53778 3/20 0.33
MAPK11 Q15759 3/20 0.33
MAPK14 Q16539 3/20 0.33
KDM4E B2RXH2 2/20 0.32
MAPT P10636 2/20 0.32
HTT P42858 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
RECQL P46063 1/20 0.32
HPGD P15428 1/20 0.31
CRHBP P24387 1/20 0.31
CRHR2 Q13324 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177230 0.92 LMNA (0.40) LMNAALDH1A1GAARORCMEN1
SCHEMBL7181631 0.89 ALDH1A1 (0.33) LMNAALDH1A1GAAMEN1KMT2A
SCHEMBL7180959 0.88 LMNA (0.36) LMNAALDH1A1GAAMEN1KMT2A
SCHEMBL7188758 0.88 MEN1 (0.43) LMNAALDH1A1GAARORCMEN1
SCHEMBL7184882 0.88 LMNA (0.35) LMNAALDH1A1GAAMEN1KMT2A
SCHEMBL7174862 0.87 GFER (0.35) LMNAALDH1A1GAAMEN1KMT2A
SCHEMBL7180482 0.87 ALDH1A1 (0.33) LMNAALDH1A1GAAMEN1KMT2A
SCHEMBL7177503 0.87 LMNA (0.36) LMNAALDH1A1GAARORCMEN1
SCHEMBL7175611 0.87 LMNA (0.40) LMNAALDH1A1GAARORCMEN1
SCHEMBL7174655 0.86 RORC (0.37) LMNAALDH1A1GAARORCMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 LMNA 3241/4885ALDH1A1 3416/4885GAA 4753/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 LMNA 3247/4885ALDH1A1 3984/4885GAA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.